丹麦制药巨头诺和诺德（NVO）周三盘前股价再度大跌5.06%，延续前一交易日的跌势。此前一天，公司因下调全年业绩预期和更换CEO，股价暴跌21.83%。
诺和诺德将2025年销售增长预期从13%-21%下调至8%-14%，营业利润增长预期从16%-24%下调至10%-16%。公司表示，这主要是由于其明星减肥药Wegovy在美国市场的销售表现不及预期，受到"不安全且非法的大规模仿制药"持续冲击影响。此外，公司的糖尿病药物Ozempic也面临来自礼来公司等竞争对手的激烈竞争。
在业绩预警的同时，诺和诺德宣布任命国际业务负责人Maziar Mike Doustdar为新任首席执行官，将于8月7日正式生效。新任CEO面临着重振公司业绩、应对市场竞争等诸多挑战。
受此利空消息影响，诺和诺德股价连续两个交易日大幅下挫。公司股价今年以来已累计下跌超过40%，较去年高点跌去近三分之二。投资者对公司未来前景的担忧情绪明显加剧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.